{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:05:10Z","timestamp":1789790710323,"version":"4.0.1"},"reference-count":43,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7715-26","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:11:43Z","timestamp":1789423903000},"source":"Crossref","is-referenced-by-count":0,"title":["Current Management of Primary Sclerosing Cholangitis (PSC) ~A Proposal for Early-stage PSC~"],"prefix":"10.2169","author":[{"given":"Hiroyuki","family":"Isayama","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Fukuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneo","family":"Ikemura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Tomishima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Umetsu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohama-shi Tobu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Naitoh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University Midori Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Radiology, Juntendo University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Notohara","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hirata","sequence":"additional","affiliation":[{"name":"Division of Advanced Genome Medicine, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Isayama H, Tazuma S, Kokudo N, et al. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol 53: 1006-1034, 2018.","DOI":"10.1007\/s00535-018-1484-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nakazawa T, Notohara K, Tazuma S, et al. The 2016 diagnostic criteria for primary sclerosing cholangitis. J Gastroenterol 52: 838-844, 2017.","DOI":"10.1007\/s00535-016-1286-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Naitoh I, Isayama H, Akamatsu N, et al. The 2024 diagnostic criteria for primary sclerosing cholangitis. J Gastroenterol 60: 1221-1231, 2025.","DOI":"10.1007\/s00535-025-02265-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fujisawa T, Ushio M, Takahashi S, et al. Role of peroral cholangioscopy in the diagnosis of primary sclerosing cholangitis. Diagnostics (Basel) 10: 268, 2020.","DOI":"10.3390\/diagnostics10050268"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yoshida H, Shiokawa M, Kuwada T, et al. Anti-integrin \u03b1v\u03b26 autoantibodies in patients with primary sclerosing cholangitis. J Gastroenterol 58: 778-789, 2023.","DOI":"10.1007\/s00535-023-02006-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yasuda M, Shiokawa M, Kuwada T, et al. Anti-integrin \u03b1v\u03b26 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study. J Gastroenterol 60: 118-126, 2025.","DOI":"10.1007\/s00535-024-02169-w"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Grigoriadis A, Imeen Ringe K, Bengtsson J, et al. Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. JHEP Rep 4: 100595, 2022.","DOI":"10.1016\/j.jhepr.2022.100595"},{"key":"8","unstructured":"8. Akiyama S, Park SH, Baek JE, et al. Prevalence and outcomes of primary sclerosing cholangitis in inflammatory bowel disease: a multinational study across Asia. Clin Gastroenterol Hepatol. Forthcoming."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 4: 492-503, 2019.","DOI":"10.1038\/s41564-018-0333-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Iwasawa K, Suda W, Tsunoda T, et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. Gut 66: 1344-1346, 2017.","DOI":"10.1136\/gutjnl-2016-312533"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan--analysis of 192 cases. J Gastroenterol 32: 134-137, 1997.","DOI":"10.1007\/BF01213311"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takikawa H, Takamori Y, Tanaka A, et al. Analysis of 388 cases of primary sclerosing cholangitis in Japan; presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 29: 153-159, 2004.","DOI":"10.1016\/j.hepres.2004.03.006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tanaka A, Tazuma S, Okazaki K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci 21: 43-50, 2014.","DOI":"10.1002\/jhbp.50"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tanaka A, Tazuma S, Nakazawa T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. J Hepatobiliary Pancreat Sci 24: 217-225, 2017.","DOI":"10.1002\/jhbp.432"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tanaka A, Mori M, Matsumoto K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res 49: 881-889, 2019.","DOI":"10.1111\/hepr.13342"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Barner-Rasmussen N, Pukkala E, Jussila A, et al. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol 55: 74-81, 2020.","DOI":"10.1080\/00365521.2019.1707277"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 102: 1042-1049, 2007.","DOI":"10.1111\/j.1572-0241.2007.01103.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Toy E, Balasubramanian S, Selmi C, et al. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol 11: 83, 2011.","DOI":"10.1186\/1471-230X-11-83"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Akamatsu N, Hasegawa K, Egawa H, et al. Donor age (\u226545 years) and reduced immunosuppression are associated with the recurrent primary sclerosing cholangitis after liver transplantation - a multicenter retrospective study. Transpl Int 34: 916-929, 2021.","DOI":"10.1111\/tri.13852"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 18: 2270-2276, 2012.","DOI":"10.1002\/ibd.22938"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Watanabe T, Nakai Y, Mizuno S, et al. Prognosis of primary sclerosing cholangitis according to age of onset. J Hepatobiliary Pancreat Sci 28: 1115-1120, 2021.","DOI":"10.1002\/jhbp.952"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Umetsu S, Notohara K, Nakazawa T, et al. Long-term outcomes of pediatric-onset primary sclerosing cholangitis: a single-center experience in Japan. Hepatol Res 49: 1386-1397, 2019.","DOI":"10.1111\/hepr.13421"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58: 2045-2055, 2013.","DOI":"10.1002\/hep.26565"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56: 48-54, 2002.","DOI":"10.1067\/mge.2002.125367"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol 28: 383-390, 2016.","DOI":"10.1097\/MEG.0000000000000576"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 77: 761-806, 2022.","DOI":"10.1016\/j.jhep.2022.05.011"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Jendrek ST, Gotthardt D, Nitzsche T, et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut 66: 137-144, 2017.","DOI":"10.1136\/gutjnl-2016-311739"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Arizumi T, Tazuma S, Isayama H, et al. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis. J Gastroenterol 57: 902-912, 2022.","DOI":"10.1007\/s00535-022-01914-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Trauner M, Chung C, Sterling K, et al. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. BMC Gastroenterol 23: 75, 2023.","DOI":"10.1186\/s12876-023-02653-2"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Trauner M, Levy C, Tanaka A, et al. Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 11: 46-58, 2026.","DOI":"10.1016\/S2468-1253(25)00208-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Mizuno S, Hirano K, Tada M, et al. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol 45: 758-762, 2010.","DOI":"10.1007\/s00535-010-0204-x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Mizuno S, Hirano K, Isayama H, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 22: 766-770, 2015.","DOI":"10.1002\/jhbp.281"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Shah A, Crawford D, Burger D, et al. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis. Semin Liver Dis 39: 432-441, 2019.","DOI":"10.1055\/s-0039-1688501"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Levy C, Abouda GF, Bilir BM, et al. Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial. J Hepatol 84: 74-85, 2026.","DOI":"10.1016\/j.jhep.2025.04.025"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis--a pilot study. Aliment Pharmacol Ther 37: 604-612, 2013.","DOI":"10.1111\/apt.12232"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Rahimpour S, Nasiri-Toosi M, Khalili H, et al. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointest Liver Dis 25: 457-464, 2016.","DOI":"10.15403\/jgld.2014.1121.254.rah"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ricciuto A, Liu K, El-Matary W, et al. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): a matched analysis from the Paediatric PSC Consortium. Aliment Pharmacol Ther 59: 1236-1247, 2024.","DOI":"10.1111\/apt.17936"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ichikawa M, Nakamoto N, Kredo-Russo S, et al. Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis. Nat Commun 14: 3261, 2023.","DOI":"10.1038\/s41467-023-39029-9"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Ishikawa D, Zhang X, Nagahara A. Current applications and future prospects of fecal microbiota transplantation. Juntendo Med J 71: 68-75, 2025.","DOI":"10.14789\/ejmj.JMJ24-0045-R"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Mizuno S, Uchida Y, Ando S, et al. Endoscopic management of primary sclerosing cholangitis. Dig Endosc 37: 723-732, 2025.","DOI":"10.1111\/den.15010"},{"key":"41","unstructured":"41. von Seth E, Karlsen TH, Tanaka A, et al. Primary sclerosing cholangitis. Lancet. Forthcoming."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Bj\u00f6rnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134: 975-980, 2008.","DOI":"10.1053\/j.gastro.2008.01.042"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Bj\u00f6rnsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 51: 731-735, 2002.","DOI":"10.1136\/gut.51.5.731"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7715-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:30:51Z","timestamp":1789788651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7715-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":43,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7715-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7715-26"}}